Michael Verneris, MD

Provider's Specialties

Hematology/Oncology - Pediatric

Provider's location(s)

Anschutz Medical Campus, Aurora

View map

Patient ratings

Patient ratings and reviews are not available

Why?

Center for Cancer and Blood Disorders

(720)777-6740

Insurance plans accepted

We participate with most major health insurance plans and national transplant networks.

View the full list

Prepare for your visit

We want to make sure you know what to expect before you arrive.

See the checklist

My care philosophy

My care philosophy is to, first and foremost, be honest and forthright with information. I believe that it only in this way that parents and patients can make the best decisions about their care. I also try to engage both the family and the patient in the decision making process when it is possible and appropriate.

Get to know Michael Verneris, MD

Departments and Programs

Languages spoken

English

Experience and background

My clinical and laboratory interests are in the area of leukemia and in using the immune system to treat cancer, whether that be through bone marrow transplantation or cellular immunotherapy.

Undergraduate 1987

Syracuse University (NY)

Medical Education 1992

Dartmouth Medical School

Internship 1992

Children's National Medical Center/George Washington University Program

Residency 1995

Children's National Medical Center/George Washington University Program

Fellowship 1998

Stanford Hospital and Clinics Program

For Patients:
My laboratory focuses on developing genetically modified T cells, specifically CAR T cells, to effectively target solid tumors. Our research aims to enhance CAR T cell homing, survival, and function within the tumor microenvironment, overcoming key barriers to their efficacy. By optimizing these properties, we seek to improve therapeutic outcomes and advance next-generation immunotherapies for solid tumors.

For Referring Providers:
My laboratory focuses on developing genetically modified T cells, specifically CAR T cells, to effectively target solid tumors. Our research aims to enhance CAR T cell homing, survival, and function within the tumor microenvironment, overcoming key barriers to their efficacy. By optimizing these properties, we seek to improve therapeutic outcomes and advance next-generation immunotherapies for solid tumors.